Comparative real-world outcomes of tirzepatide vs semaglutide in patients with obesity and type2 diabetes: A retrospective propensity-matched cohort study.

What the trial testedas reported · 47,804 people

Not counted

−8%−14% to −2%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.918, 95% CI 0.86–0.98

Not counted

−56%−66% to −44%

Bigger than 9 in 10 for all-cause mortality

As reported

RR 0.436, 95% CI 0.34–0.56 · the paper's word: All-cause mortality

Not counted

−4%−8% to −0%

Bigger than 2 in 10 for adverse events & safety

As reported

RR 0.959, 95% CI 0.92–1.00

the abstract, start to end

… incidence of MACE at "("3.7% vs 4.1% (RR 0.918, 95% CI 0.862-0.978).

… tirzepatide (0.2% vs. 0.4%; Risk Ratio 0.436, 95% CI 0.338-0.562).

… cohort (9.8% vs. 10.2%; Risk Ratio 0.959, 95% CI 0.924-0.997), while …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

RR 0.9180.86–0.98

All-cause mortality

RR 0.4360.34–0.56

Adverse events & safety

RR 0.9590.92–1.00

GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsCardiovascular eventsAll-cause mortalityAdverse events & safety

1 / 3